Product Pipeline

Pipeline Overview

Product Mechanism Ownership Indication Preclinical Clinical Proof-of-Concept Pivotal
HM43239 Myeloid Kinome Aptose WW AML
complete
AML Preclinical Phase complete
in progress
Clinical Proof-of-Concept Phase in progress
not started
Pivotal Phase not started
Luxeptinib Lymphoid Kinome Aptose: WW
Crystal Genomics: Korea
CLL & NHL
complete
CLL & NHL Preclinical Phase complete
in progress
Clinical Proof-of-Concept Phase in progress
not started
Pivotal Phase not started
Luxeptinib Myeloid Kinome Aptose: WW
Crystal Genomics: Korea
AML & MDS
complete
AML & MDS Preclinical Phase complete
in progress
Clinical Proof-of-Concept Phase in progress
not started
Pivotal Phase not started
APTO-253 MYC Aptose: WW AML & MDS
complete
AML & MDS Preclinical Phase complete
in progress
Clinical Proof-of-Concept Phase in progress
not started
Pivotal Phase not started
APL-581 BRD4/JAK Aptose and Ohm Hematologic Cancers
in progress
Hematologic Cancers Preclinical Phase in progress
not started
Clinical Proof-of-Concept Phase not started
not started
Pivotal Phase not started
Luxeptinib for B-cell Tumors

Luxeptinib for B-cell Tumors

Oral, Mutation-Agnostic, Dual Lymphoid / Myeloid Kinome Inhibitor (LKI/MKI)

Luxeptinib is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

View Candidate
Luxeptinib for Myeloid Tumors

Luxeptinib for Myeloid Tumors

Oral, Mutation-Agnostic, Dual Lymphoid / Myeloid Kinome Inhibitor (LKI/MKI)

Luxeptinib is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.

View Candidate
HM43239 for Myeloid Tumors

HM43239 for Myeloid Tumors

Oral, Potent Myeloid Kinome Inhibitor (MKI)

HM43239 is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).

View Candidate
Posters & Presentations

Posters & Presentations

Our online library includes numerous publications, including presentations, posters, and other media that provide additional information on preclinical and clinical studies of our drug candidates.

View Posters & Presentations